Ariana Thacker's MoldCo raises $8M to tackle mold-related illness with testing and virtual care
Sep 19, 2025 with Ariana Thacker
Key Points
- MoldCo raises $8 million in seed funding from Cantos and Collaborative Fund to scale testing and virtual care for mold-related illness, positioning itself as the first commercialized player around the Shoemaker Protocol.
- The startup claims the largest proprietary dataset in mold illness and is building a parent company structure to spin out ventures targeting adjacent biotoxin conditions tied to immune system dysregulation.
- Customer acquisition runs across podcasts, social media, and organic referrals, with a recent content push generating 7 million views in one week; founder is explicit about not pursuing legal or real estate integration near-term.
Summary
Ariana Thacker, founder of MoldCo, has raised $8 million in a seed round led by Cantos and Collab Fund, announced in September 2025. The raise was completed earlier in the year with a delayed public disclosure.
MoldCo operates under a parent entity called The Immune Co, which plans to spin out additional ventures — Limeco and LongCo — targeting other biotoxin-related conditions tied to innate immune system dysregulation. The thesis is that mold illness data, specifically around chronic inflammatory response syndrome (CIRS), provides a research foundation applicable to adjacent chronic inflammation conditions.
The core business has two pillars: diagnostics and virtual care.
- On the lab side, MoldCo offers four tests via its website, including a 3-panel and a 16-panel blood draw through LabCorp, HLA genetic susceptibility testing (relevant to roughly 1 in 4 Americans), and a low-cost home surface swab test using a Swiffer pad.
- On the care side, the company runs a virtual clinic built around the Shoemaker Protocol, described as the only peer-reviewed treatment framework in the mold illness space, backed by hundreds of publications. In-house providers deliver care through a concierge model and patient portal designed for cost efficiency at scale.
The founding team includes the researchers credited with defining CIRS and developing its biomarkers and treatment protocols over 30 years of work. MoldCo also claims the largest proprietary dataset in the field, which feeds an active R&D arm.
Customer acquisition is running across multiple channels. A recently launched content operation generated 7 million views in roughly one week across TikTok and Instagram. At least 15% of the patient base comes from referrals, a channel Thacker says has not yet been formally optimized. Thacker has appeared on at least 30 podcasts and ran a viral Reddit AMA with founding physician Dr. Shoemaker.
Thacker is explicit about where MoldCo is not going, at least near-term. Legal support for tenants fighting landlords is outside current scope. Deep integration into the home-buying or rental decision process is also deprioritized, with Thacker framing the environmental remediation side as structurally harder to solve than the healthcare side. She notes that new construction carries significant mold risk due to outdoor material exposure and trade-offs embedded in modern energy efficiency standards, but sees that as an opening for other founders rather than a MoldCo expansion.